Healthcare Sales & Marketing Network News: cytokines

Searching News Database: cytokines

HSMN NewsFeed - 12 Feb 2025
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 16 Jan 2025
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX(R) (bimekizumab-bkzx)
Biopharmaceuticals Drug Delivery Product Launch

HSMN NewsFeed - 23 Sep 2024
UCB Announces U.S. FDA Approvals for BIMZELX(R) (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Apr 2024
Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 Aug 2023
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 16 Jun 2023
VIVEX Biologics, Inc. Launches New CYGNUS(R) Dual Amniotic Allograft
Devices Wound Care Product Launch

HSMN NewsFeed - 27 Mar 2023
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn(R) for the Treatment of ALS
Regenerative Medicine Neurology FDA

HSMN NewsFeed - 2 Feb 2023
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 19 Jan 2023
Halia Therapeutics Appoints Former Amgen Executive, Margit M. Janát-Amsbury, MD, Ph.D., as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Dec 2022
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn(R)
Regenerative Medicine Neurology FDA

HSMN NewsFeed - 10 Nov 2022
BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS
Biopharmaceuticals Regenerative Medicine Neurology FDA

HSMN NewsFeed - 2 Nov 2022
'Enhanced Lung Rest' with CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients with Refractory Lung Failure from Five Major U.S. Hospitals
Devices

HSMN NewsFeed - 15 Sep 2022
BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn(R) Phase 2 Progressive MS Trial in Multiple Sclerosis Journal
Regenerative Medicine Neurology

HSMN NewsFeed - 14 Apr 2022
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Dec 2021
FDA Authorizes Further NurOwn(R) Dosing Under Expanded Access Program
Regenerative Medicine Neurology FDA

HSMN NewsFeed - 21 Dec 2021
Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study
Biopharmaceuticals Dermatology

HSMN NewsFeed - 20 Dec 2021
CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb(R) in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
Devices

HSMN NewsFeed - 5 Nov 2021
SeaStar Medical Presents Data from SCD 005 Clinical Study at the American Society of Nephrology (ASN) Kidney Week 2021 Annual Meeting
Devices

HSMN NewsFeed - 30 Sep 2021
OLUMIANT(R) Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata
Biopharmaceuticals

HSMN NewsFeed - 18 Aug 2021
Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 16 Aug 2021
Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials
Biopharmaceuticals Dermatology

HSMN NewsFeed - 6 Jul 2021
Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additions to Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Mar 2021
Bioniz Therapeutics Appoints Dr. Alexandre Kaoukhov to Leadership Team
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Feb 2021
Therapeutic Solutions International Acquires Stem Cell Therapy That Successfully Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung Disease
Regenerative Medicine Acquisitions

HSMN NewsFeed - 19 Jan 2021
Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 7 Jan 2021
Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 22 Dec 2020
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
Biopharmaceuticals

HSMN NewsFeed - 14 Dec 2020
BrainStorm Announces NurOwn(R) Expanded Access Program
Regenerative Medicine Neurology Product Launch

HSMN NewsFeed - 23 Nov 2020
BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
Regenerative Medicine Neurology

HSMN NewsFeed - 23 Nov 2020
Innovent Announces NMPA Granted New Indication Approval for SULINNO(R) (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 17 Nov 2020
BrainStorm Announces Topline Results from NurOwn(R) Phase 3 ALS Study
Regenerative Medicine Neurology

HSMN NewsFeed - 10 Nov 2020
Cytocom, Inc. Appoints Taunia Markvicka, PharmD., MBA, Chief Operating Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Nov 2020
Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma
Biopharmaceuticals

HSMN NewsFeed - 12 Oct 2020
OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 21 Sep 2020
Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100(TM) and Selection of Commercial Partners
Biopharmaceuticals

HSMN NewsFeed - 18 Sep 2020
CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 3 Sep 2020
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
Biopharmaceuticals Regulatory

HSMN NewsFeed - 10 Aug 2020
Werewolf Therapeutics Appoints Business Leader, Ellen Lubman, as Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Aug 2020
FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 24 Jul 2020
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
Biopharmaceuticals Dermatology

HSMN NewsFeed - 20 Jul 2020
FDA Clears Abivertinib for Phase 2 Safety and Efficacy Study in Hospitalized Patients with Moderate To Severe Covid-19
Biopharmaceuticals FDA

HSMN NewsFeed - 24 Jun 2020
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
Regenerative Medicine Neurology

HSMN NewsFeed - 3 Jun 2020
Novo Ventures Leads US$55M Series B Investment in NodThera
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 1 Jun 2020
Lilly's Taltz(R) (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Biopharmaceuticals FDA

HSMN NewsFeed - 27 May 2020
BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research
Regenerative Medicine Neurology Personnel

HSMN NewsFeed - 13 Apr 2020
U.S. FDA Grants CytoSorb(R) Emergency Use Authorization for Use in Patients with COVID-19 Infection
Devices FDA

HSMN NewsFeed - 31 Mar 2020
CytoSorb(R) Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care
Devices Regulatory

HSMN NewsFeed - 30 Mar 2020
Lilly's Taltz(R) (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 16 Mar 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Biopharmaceuticals FDA

HSMN NewsFeed - 17 Feb 2020
PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Jan 2020
Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 22 Jan 2020
PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 9 Jan 2020
Bioniz Therapeutics enters into an option agreement for acquisition by Almirall of its lead clinical candidate BNZ-1 in development for immuno-dermatologic and onco-dermatologic diseases
Biopharmaceuticals Dermatology Mergers & Acquisitions

HSMN NewsFeed - 20 Nov 2019
Werewolf Therapeutics Launches with $56M Series A Financing to Develop Transformative Immuno-Stimulatory Cancer Medicines
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 12 Nov 2019
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis
Biopharmaceuticals

HSMN NewsFeed - 12 Nov 2019
ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz(R) (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
Biopharmaceuticals

HSMN NewsFeed - 3 Oct 2019
New Head-to-Head Data Show Taltz(R) (ixekizumab) Superiority versus TREMFYA(R) (guselkumab) in People with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 30 Sep 2019
Arix Bioscience plc: Arix Co-leads EUR 20 Million Series A Investment Round in STipe Therapeutics
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 27 Aug 2019
PIONYR Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated Macrophages
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 26 Aug 2019
Lilly Receives U.S. FDA Approval for Taltz(R) (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Aug 2019
Torque Expands Leadership Team with Appointment of Sok Cheng Soh as CFO and Ana Radeljevic as VP, Head of Business Operations
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 18 Jun 2019
FDA Grants Fast Track Designation for Torque's First Deep-Primed T Cell Cancer Immunotherapy Program, TRQ-1501
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Jun 2019
Lilly Presents Positive Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology
Biopharmaceuticals

HSMN NewsFeed - 11 Jun 2019
Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz(R) (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology
Biopharmaceuticals Dermatology

HSMN NewsFeed - 6 Jun 2019
Palatin Technologies Granted FDA Orphan Drug Designation -- PL-8177 for the Treatment of Non-Infectious Uveitis
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 10 Apr 2019
OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12
Biopharmaceuticals Oncology Drug Delivery

HSMN NewsFeed - 17 Dec 2018
Lilly Announces Positive Top-Line Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
Biopharmaceuticals

HSMN NewsFeed - 13 Dec 2018
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Nov 2018
FDA Approves Gamifant(R) (emapalumab), the First and Only Treatment for Primary Haemophagocytic Lymphohistiocytosis (HLH)
Biopharmaceuticals FDA

HSMN NewsFeed - 2 Nov 2018
Torque Announces Appointment of Immunotherapy Pioneer F. Stephen Hodi, MD, to Scientific Advisory Board and Alex Bruni as COO/ CFO
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Sep 2018
Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz(R) and Tremfya(R) in Patients with Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals

HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory

HSMN NewsFeed - 25 Jul 2018
Torque Appoints James Mullen as Chairman of Board of Directors, Maykin Ho, PhD, as Strategic Advisor to the Board of Directors, and Mario Sznol, MD, to Scientific Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 12 Jul 2018
Synthorx Expands Leadership Team with Three Key Hires
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Jun 2018
Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
Biopharmaceuticals

HSMN NewsFeed - 30 Apr 2018
Synthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin(TM) Cytokines
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 14 Mar 2018
Torque Appoints John Hohneker, MD, to Board of Directors and Marcela Maus, MD, PhD, to Scientific Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Mar 2018
Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 2 Mar 2018
FDA to Review DUPIXENT(R) (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Feb 2018
AAD 2018: Treatment with Lilly's Taltz(R) (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity
Biopharmaceuticals Dermatology

HSMN NewsFeed - 13 Feb 2018
Lilly Announces Positive Top-Line Phase 3 Results for Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals

HSMN NewsFeed - 4 Jan 2018
Enterome Raises €32 Million ($38.5 Million) in a Series D Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 12 Dec 2017
DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Dec 2017
Bioniz Therapeutics Appoints Graham Cooper to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Nov 2017
Long-Term Use of Lilly's Taltz(R) (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors
Biopharmaceuticals

HSMN NewsFeed - 29 Sep 2017
Dermavant Sciences Appoints Vince Ippolito as President and Chief Operating Officer
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 24 Jul 2017
eFFECTOR Therapeutics Completes $38.6 Million Series C Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 17 Jul 2017
Medicenna Bolsters Management Team
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 Jul 2017
Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant(R) (baricitinib) for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 16 Jun 2017
EULAR 2017: Lilly's Taltz(R) (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks
Biopharmaceuticals

HSMN NewsFeed - 16 Jun 2017
New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017
Biopharmaceuticals

HSMN NewsFeed - 14 Apr 2017
U.S. FDA Issues Complete Response Letter for Baricitinib
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Mar 2017
Sanofi and Regeneron Announce FDA Approval of Dupixent(R) (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 14 Feb 2017
European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 Feb 2017
GSK Consumer Healthcare Launches FLONASE(R) Sensimist(TM) Allergy Relief Nationwide
Biopharmaceuticals Product Launch

HSMN NewsFeed - 16 Dec 2016
Janssen Submits Application Seeking FDA Approval of STELARA(R) (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 8 Dec 2016
Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent(R) (dupilumab) Accepted for Review by the EMA
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 7 Dec 2016
CytoSorb(R) Attains Permanent, Dedicated Reimbursement Code in Core Market of Germany
Devices Reimbursement

HSMN NewsFeed - 7 Dec 2016
Neovacs obtains FDA “Fast Track” designation for IFNα Kinoid in Lupus (SLE)
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Nov 2016
First Successful Treatment of Dengue Fever and Dengue Shock Syndrome Using CytoSorb(R)
Devices

HSMN NewsFeed - 22 Nov 2016
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Oct 2016
Allergan Successfully Completes Vitae Tender Offer
Biopharmaceuticals Dermatology Mergers & Acquisitions

HSMN NewsFeed - 7 Oct 2016
Rigel Expands Leadership Team in Research and Business Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Sep 2016
Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 3 Aug 2016
FDA Approves FLONASE(R) Sensimist(TM) Allergy Relief
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Aug 2016
Bioniz Therapeutics Closes Series A Financing and Appoints David Pyott as Chairman of the Board of Directors
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 25 Jul 2016
MiMedx Announces Nationwide Launch of New Ambient Temperature Version of OrthoFlo
Devices Regenerative Medicine Product Launch

HSMN NewsFeed - 12 Jul 2016
FDA Approves Shire’s Xiidra(TM) (lifitegrast ophthalmic solution) 5% – The Only Treatment Indicated for the Signs and Symptoms of Dry Eye Disease
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 18 May 2016
CytoSorb(R) Achieves Final Product Registration in Russia
Devices Distribution

HSMN NewsFeed - 3 May 2016
Bioniz Therapeutics Appoints Fredrik Wiklund as Chief Operating Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 18 Mar 2016
STELARA(R) Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 15 Sep 2015
Molecular Response Appoints the Former Head of Translational Medicine Oncology at MedImmune/AstraZeneca, Brett Hall, Ph.D., as Chief Executive Officer
Diagnostics Personnel

HSMN NewsFeed - 19 Aug 2015
Immunomedics Appoints Arthur S. Kirsch as Director
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 24 Jun 2015
ViraTherapeutics Raises €3.6 Million in the First Closing of a Series A Financing Round to Advance its Novel Oncolytic Virus Platform
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 25 Nov 2014
Eleven Biotherapeutics Announces Additional Financing of $20 Million
Biopharmaceuticals Ophthalmology Venture Capital

HSMN NewsFeed - 29 Jul 2014
AMNIOX(R) Medical Announces Initiation of Prospective, Randomized, Controlled Clinical Study of Chronic Wounds
Regenerative Medicine Wound Care

HSMN NewsFeed - 13 May 2014
Gemmus Pharma Closes $3.3M Series B Funding to Develop Superior Flu Drug
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 18 Mar 2014
Immune Design Appoints Franklin M. Berger to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Mar 2014
Immune Design Appoints William Ringo to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 7 Feb 2014
Covis Pharmaceuticals Announces Its New Expanded Dosage Options of LANOXIN(R) for Cardiac Patients With Mild-to-Moderate Heart Failure
Biopharmaceuticals Cardiology

HSMN NewsFeed - 31 Dec 2013
CytoSorbents Provides Clinical Update on CytoSorb Dosing Study
Devices

HSMN NewsFeed - 19 Dec 2013
Takeda Announces Exclusive License and Option Agreement with Natrogen for Development of Natura-alpha for Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Licensing

HSMN NewsFeed - 30 Oct 2013
Immune Design Raises Up to $49 Million Series C Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 24 Oct 2013
Celsus Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Sep 2013
Immune Design Appoints Richard T. Kenney, M.D., Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Aug 2013
Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free Survival in Previously Untreated Follicular Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Jul 2013
Pfizer Provides Update on Global Regulatory Approvals and Launches of XELJANZ(R) (tofacitinib citrate) for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 10 Jul 2013
Idera Pharmaceuticals Appoints James Geraghty as Chairman of the Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Apr 2013
CytoSorbents Announces Trauma Advisory Board
Devices Personnel

HSMN NewsFeed - 28 Nov 2012
Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
Biopharmaceuticals Wound Care Orthopaedic Acquisitions

HSMN NewsFeed - 5 Sep 2012
DERMAGRAFT(R) Approved in Canada for Treatment of Diabetic Foot Ulcers
Devices Wound Care Regulatory

HSMN NewsFeed - 20 Jun 2012
CytoSorbents Appoints Dr. Christian Steiner as VP of Sales and Marketing and Hires Core Sales Force That Marks the Official Launch of CytoSorb(R) in Germany
Devices Personnel

HSMN NewsFeed - 28 Mar 2012
Bristol-Myers Squibb and Meso Scale Discovery Enter Agreement to Develop Diagnostic Assays for Alzheimer’s Disease
Diagnostics Neurology

HSMN NewsFeed - 12 Mar 2012
Organogenesis Inc. Announces FDA Approval of GINTUIT(TM) for Oral Soft Tissue Regeneration
Regenerative Medicine Wound Care FDA

HSMN NewsFeed - 29 Feb 2012
Abbott and Galapagos Announce Global Collaboration for Novel Oral Therapy, GLPG0634, in Phase II to Treat Autoimmune Diseases
Biopharmaceuticals

HSMN NewsFeed - 9 Dec 2011
Immunomedics Creates Targeted Therapeutics for Solid Cancers
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Sep 2011
Pfizer Announces Detailed Pivotal Data for Investigational Compound Tofacitinib in Rheumatoid Arthritis to be Presented at American College of Rheumatology 2011 Annual Scientific Meeting
Biopharmaceuticals

HSMN NewsFeed - 6 Jul 2011
Coronado Biosciences Closes $25.8M in Series C Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 28 Apr 2011
Pfizer Announces Top-Line Results Of Final Two Pivotal Phase 3 Trials Of Tofacitinib (CP-690,550) In Patients With Active Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 5 Jan 2011
FDA Grants Supplemental Approval for ACTEMRA(R) (tocilizumab)
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Oct 2010
Exelixis Licenses Programs to Bristol-Myers Squibb Company
Biopharmaceuticals Licensing

HSMN NewsFeed - 6 Oct 2010
New Data Demonstrate Treatment With STELARA(R) (Black Triangle Drug) (ustekinumab) Results in Sustained Improvements in Psoriasis Severity and Quality of Life up to Three Years
Biopharmaceuticals Dermatology

HSMN NewsFeed - 19 May 2010
STELARA(TM) Significantly Improves Symptoms of Depression, Anxiety and Health-Related Quality of Life in Patients With Moderate to Severe Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 16 Mar 2010
Genentech Submits Supplemental Biologics License Application for ACTEMRA(R) (tocilizumab) for Prevention of Structural Joint Damage and Improvement of Physical Function in Rheumatoid Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 17 Feb 2010
Eleven Biotherapeutics Completes $35 Million Series A Funding to Advance Pipeline of Innovative Protein-Based Therapeutics
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 14 Jan 2010
STELARA(TM) (ustekinumab) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 9 Jan 2010
FDA Approves ACTEMRA(R) (tocilizumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Nov 2009
Altair Therapeutics Secures $17 Million Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 23 Sep 2009
Janssen-Cilag's STELARA(R) (Black Triangle Drug) (ustekinumab) Approved by NICE for the Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 1 Sep 2009
Multiple Presentations at the European Society of Cardiology Congress Document EECP Promotes Coronary Collateral Flow Leading to Sustained Clinical Improvement
Devices Cardiology

HSMN NewsFeed - 20 Aug 2009
Sutro Biopharma Announces Additions to Board of Directors and Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Aug 2009
DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Jul 2009
Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Jun 2009
Pluristem Therapeutics Receives European Regulatory Approval for Placental-Derived Stem Cell Clinical Trial
Regenerative Medicine

HSMN NewsFeed - 26 May 2009
Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
Biopharmaceuticals

HSMN NewsFeed - 14 May 2009
Altair Therapeutics Appoints Dr. Joel Martin President and CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Apr 2009
Synageva BioPharma Announces $30 Million Equity Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 22 Jan 2009
New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 Jan 2009
TOPIGEN Pharmaceuticals Reports Phase 2 Results of TPI ASM8 in Asthma Patients
Biopharmaceuticals

HSMN NewsFeed - 4 Dec 2008
Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
Biopharmaceuticals

HSMN NewsFeed - 18 Sep 2008
Findings From Landmark Study Show Ustekinumab Demonstrated Superior Efficacy to Enbrel(R) (Etanercept) in Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 3 Sep 2008
DiaKine Therapeutics Announces Financing and New Board Member
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 4 Aug 2008
Pluristem Appoints Ms. Chaya Mazouz Clinical Operations Director
Regenerative Medicine Personnel

HSMN NewsFeed - 30 Jun 2008
Introgen Submits ADVEXIN(R) Regulatory Applications in the U.S. and Europe
Biopharmaceuticals Oncology FDA Regulatory

HSMN NewsFeed - 17 Jun 2008
FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 13 Jun 2008
ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
Biopharmaceuticals

HSMN NewsFeed - 5 Jun 2008
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
Biopharmaceuticals

HSMN NewsFeed - 28 May 2008
ADVEXIN(R) Improves Survival in Recurrent, Refractory Head and Neck Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 May 2008
American Academy of Dermatology Issues New Guidelines for the Management of Psoriasis and Psoriatic Arthritis
Dermatology

HSMN NewsFeed - 12 May 2008
Pipex Pharmaceuticals Receives FDA Orphan Drug Designation for Oral TTM for Idiopathic Pulmonary Fibrosis (IPF)
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Apr 2008
InterMune Announces Progress on Pirfenidone in IPF
Biopharmaceuticals

HSMN NewsFeed - 20 Mar 2008
International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
Biopharmaceuticals

HSMN NewsFeed - 4 Mar 2008
Pluristem Submits Pre-IND Application in Germany to Initiate Clinical Trials of PLX-PAD for Peripheral Artery Disease
Regenerative Medicine Regulatory

HSMN NewsFeed - 13 Feb 2008
VLST Corporation Announces Board and Executive Management Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Feb 2008
Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers
Devices Wound Care

HSMN NewsFeed - 11 Feb 2008
SciClone and Sigma-Tau Report Promising Interim Results From Phase 3 Hepatitis C Trial
Biopharmaceuticals

HSMN NewsFeed - 4 Feb 2008
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 1 Feb 2008
MediciNova's MN-166 Reduces Persistent Black Hole Formation in Multiple Sclerosis Patients
Biopharmaceuticals Neurology

HSMN NewsFeed - 29 Jan 2008
Pipex Pharmaceuticals Provides Update on COPREXA (Oral Tetrathiomolybdate) New Drug Application
Biopharmaceuticals Neurology

HSMN NewsFeed - 9 Jan 2008
Ortec Shareholders Approve Corporate Name Change to Forticell Bioscience, Inc.
Regenerative Medicine Wound Care

HSMN NewsFeed - 8 Jan 2008
Pluristem Announces Second Clinical Indication Revascularization Effect After PLX-PAD Therapy
Regenerative Medicine

HSMN NewsFeed - 20 Dec 2007
Hollis-Eden Pharmaceuticals Announces Cystic Fibrosis Foundation Therapeutics Selects TRIOLEX(TM) (HE3286) as a Next-Generation Oral Anti-Inflammatory Drug Candidate
Biopharmaceuticals

HSMN NewsFeed - 20 Dec 2007
Introgen Plans to Expand Biomarker Database in Phase 3 Trials and File BLA and MAA for ADVEXIN in Advanced Head and Neck Cancer in First Half of 2008
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Dec 2007
Osiris Therapeutics Reports Positive Results for Prochymal(TM) as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease
Regenerative Medicine

HSMN NewsFeed - 5 Dec 2007
Amarin Signs Agreement to Acquire Ester Neurosciences
Biopharmaceuticals Neurology Mergers & Acquisitions

HSMN NewsFeed - 4 Dec 2007
Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals FDA Regulatory

HSMN NewsFeed - 27 Nov 2007
Introgen's ADVEXIN Advances as Marketing Authorization Application is Accepted for Review in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 27 Nov 2007
Gendux Announces Acceptance of Its ADVEXIN Marketing Authorization Application for Review by the EMEA
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 26 Nov 2007
InterMune Buys Out License Agreement for Pirfenidone
Biopharmaceuticals Licensing

HSMN NewsFeed - 21 Nov 2007
Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 15 Nov 2007
Introgen Therapeutics Highlights Summary ADVEXIN Data at the Third International Workshop on Mutant p53 and the Symposium on Li-Fraumeni Syndrome
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Nov 2007
Introgen and Gendux Submit First Marketing Authorization Application for ADVEXIN
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Nov 2007
Lodotra(TM) Shows a Sustained Reduction of Morning Stiffness in Patients with Rheumatoid Arthritis Treated with Lodotra(TM) for 12 Months
Biopharmaceuticals

HSMN NewsFeed - 15 Oct 2007
Pipex Pharmaceuticals Appoints David A. Newsome, M.D. as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Oct 2007
ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Oct 2007
Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 27 Sep 2007
Introgen Presents Biomarker Data Demonstrating Abnormal p53 Predicts ADVEXIN Efficacy in Head and Neck, Lung, Prostate and Li-Fraumeni Cancers
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Sep 2007
Pipex Pharmaceuticals Plans November NDA Filing for COPREXA Based on Pre-NDA Meetings With FDA
Biopharmaceuticals Neurology

HSMN NewsFeed - 17 Sep 2007
Vasogen Plans Confirmatory Study of Celacade(TM) in Chronic Heart Failure to Support U.S. Regulatory Approval
Biopharmaceuticals Cardiology

HSMN NewsFeed - 12 Sep 2007
Innocoll Enters Into Collaboration With TGR Biosciences for Development of a Novel Wound Healing Product
Biopharmaceuticals Drug Delivery Wound Care

HSMN NewsFeed - 13 Aug 2007
Avigen Initiates U.S. Clinical Development for AV411
Biopharmaceuticals

HSMN NewsFeed - 30 Jul 2007
MedaSorb to Pursue 6 Billion Dollar Sepsis Market in Europe
Devices Regulatory

HSMN NewsFeed - 25 Jul 2007
Fourth ACTEMRA(TM) (tocilizumab) Phase III Study Demonstrates Significant Clinical Benefit in RA Patients
Biopharmaceuticals

HSMN NewsFeed - 11 Jul 2007
Ortec International: Dr. Costa Papastephanou Appointed CEO
Regenerative Medicine Wound Care Personnel

HSMN NewsFeed - 10 Jul 2007
ACTEMRA(TM) (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 15 Jun 2007
Rexahn Pharmaceuticals, Inc. Appoints Dr. Freddie Ann Hoffman to the Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Jun 2007
ACTEMRA(TM) (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
Biopharmaceuticals

HSMN NewsFeed - 12 Jun 2007
CEL-SCI Receives US FDA Orphan Drug Designation for Its Cancer Drug Multikine(R)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Jun 2007
Introgen Announces Positive Phase 2 Clinical Trial Results with INGN 225 Immunotherapy in Patients with Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Survival Benefit Demonstrated in Placebo-Controlled Trial in Patients with Refractory Non-Small Cell Lung Cancer Treated with Agennix's Oral Talactoferrin
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Oxford Biomedica and Sanofi-Aventis Report new TroVax(R) Phase II Trial Results in Renal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2007
Introgen's ADVEXIN Demonstrates Clinical Benefit in Inherited Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 May 2007
CollaGenex Pharmaceuticals and QuatRx Pharmaceuticals Announce Agreement for the Development and Commercialization of Becocalcidiol
Biopharmaceuticals Dermatology Licensing

HSMN NewsFeed - 7 May 2007
AEterna Zentaris Bolsters Management Team with Two Key Positions Named
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 May 2007
CollaGenex Pharmaceuticals Discontinues 40 mg Cohort of Phase II Dose-Finding Study of Incyclinide for the Treatment of Acne
Biopharmaceuticals Dermatology

HSMN NewsFeed - 2 May 2007
CollaGenex Pharmaceuticals Provides Update on 40 mg Cohort of Phase II Dose-Finding Study of Incyclinide for the Treatment of Acne
Biopharmaceuticals Dermatology

HSMN NewsFeed - 30 Apr 2007
Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory Dose Doxycycline for the Treatment of Rosacea
Biopharmaceuticals Dermatology

HSMN NewsFeed - 24 Apr 2007
New TNS(R) Serum From SkinMedica(R) Exclusively Applied Through HydraFacial MD(TM) by Edge Systems
Biopharmaceuticals Dermatology

HSMN NewsFeed - 23 Apr 2007
CollaGenex Pharmaceuticals Provides Update on Examination of Incyclinide Patent Application
Biopharmaceuticals Dermatology

HSMN NewsFeed - 18 Apr 2007
Pipex Pharmaceuticals Appoints Kay E. Stremler, Ph.D. as Vice President of Manufacturing
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Apr 2007
Vasogen and Grupo Ferrer Form Collaboration to Commercialize Celacade(TM) in the European Union
Biopharmaceuticals Devices Cardiology

HSMN NewsFeed - 14 Apr 2007
ARIAD files claim against Amgen and Wyeth Alleging Infringement of NF-(kappa)B Patent by Enbrel(R) and Kineret(R)
Biopharmaceuticals Litigation

HSMN NewsFeed - 27 Mar 2007
MediciNova Announces Positive Clinical Results From MN-166 Phase II Multiple Sclerosis Trial
Biopharmaceuticals Neurology

HSMN NewsFeed - 14 Mar 2007
Tragara Pharmaceuticals, Inc. Announces Corporate Launch and Series A Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 26 Feb 2007
Ortec Initiates Premarket Approval (PMA) Application Filing Seeking Approval for OrCel(R) in Treating Venous Leg Ulcers
Regenerative Medicine Wound Care FDA

HSMN NewsFeed - 2 Feb 2007
Positive Results of Phase 4 Clinical Study Evaluating Effects of Oracea(TM) (doxycycline, USP) Capsules, 40 mg, in Combination with MetroGel(R) (metronidazole gel), 1%, as Treatment for Rosacea Presented at Annual Meeting of the AAD
Biopharmaceuticals Dermatology

HSMN NewsFeed - 24 Jan 2007
Introgen Reports that INGN 241 in Combination with Avastin(R) Results in Complete Tumor Regression
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Jan 2007
Phase III ACTEMRA(TM) (tocilizumab) Study Results Demonstrate Significant Improvement in Signs and Symptoms of Patients with Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 16 Jan 2007
CEL-SCI Receives Green Light From FDA to Proceed With Phase III Cancer Study
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Jan 2007
Osiris Therapeutics Receives FDA Fast Track Status for Its Crohn's Disease Stem Cell Therapy and Clearance to Start Phase III Clinical Trial
Regenerative Medicine Gastroenterology

HSMN NewsFeed - 28 Dec 2006
SciClone and Sigma-Tau Complete Enrollment in Phase 3 Triple Therapy Hepatitis C Clinical Trial
Biopharmaceuticals

HSMN NewsFeed - 20 Dec 2006
CollaGenex Pharmaceuticals Signs License and Supply Agreement with MediGene for Marketing Rights to Oracea in EU and Certain Other Countries
Biopharmaceuticals Dermatology Licensing

HSMN NewsFeed - 11 Dec 2006
Introgen Announces New Clinical Data Confirming ADVEXIN(R) Survival Benefit
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2006
Osiris Therapeutics Provides Update on Phase II Trial Evaluating PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals

HSMN NewsFeed - 13 Nov 2006
New Study Shows ACTEMRA(TM) (tocilizumab) Significantly Improves Remission Rates in Patients with Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 9 Nov 2006
Two-Year Data for ORENCIA(R) (abatacept) Demonstrate Continued Efficacy in Adults With Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 9 Nov 2006
Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals Regenerative Medicine

HSMN NewsFeed - 6 Nov 2006
Pipex Therapeutics Merges With Sheffield Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 3 Nov 2006
Introgen Obtains Exclusive License to Therapies Combining Epidermal Growth Factor Drugs and Tumor Suppressor Genes
Biopharmaceuticals Licensing Oncology

HSMN NewsFeed - 31 Oct 2006
Introgen Therapeutics and Gendux AB Announce Agreement With European Medicines Agency to File for ADVEXIN Approval Under Exceptional Circumstance Rules
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 17 Oct 2006
Introgen's ADVEXIN Molecular Targeted Therapy Is Active in Multiple Cancers; ADVEXIN Regulatory Program Advances
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Oct 2006
Agennix Receives FDA Orphan Drug Designation for Talactoferrin Alfa in Renal Cell Carcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Oct 2006
Agennix Receives FDA Fast Track Designation for Talactoferrin Alfa in Non-Small Cell Lung Cancer and Diabetic Foot Ulcers
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Oct 2006
Nephros Announces Positive Results of Clinical Study for Olpur MD190 Mid-Dilution Hemodiafiltration Filter
Devices

HSMN NewsFeed - 4 Oct 2006
SkyePharma Reports Positive Phase III and EU Filing for Lodotra(TM)
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 29 Sep 2006
FDA Issues Approvable Letter to Ortec for Use of Cryopreserved OrCel(R) in Epidermolysis Bullosa Patients' Hand Reconstructions and Donor Sites
Regenerative Medicine FDA

HSMN NewsFeed - 12 Sep 2006
Ortec Announces Positive Results in Confirmatory Venous Leg Ulcer Trial
Devices Wound Care Regenerative Medicine

HSMN NewsFeed - 17 Jul 2006
Cambrex and Ortec Submit to FDA a Humanitarian Device Exemption (HDE) for OrCel(R) to Treat Epidermolysis Bullosa Patients
Devices

HSMN NewsFeed - 6 Jul 2006
Ortec Issues Update on Its Three Technology Platforms for Regenerative Medicine and Stem Cells
Regenerative Medicine

HSMN NewsFeed - 22 Jun 2006
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
Biopharmaceuticals

HSMN NewsFeed - 2 Jun 2006
Introgen's ADVEXIN p53 Therapy Demonstrates Clinical Benefit in Inherited Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2006
CollaGenex Pharmaceuticals Receives FDA Approval for Oracea(TM)
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 26 May 2006
Introgen to Announce Important New Clinical Data for ADVEXIN Cancer Therapy at Major Medical Meetings
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 May 2006
CEL-SCI Presents Long-Term Survival Data With Its Anti-Cancer Drug Multikine(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 May 2006
Cyberonics Provides Update on Annual American Psychiatric Association Meeting Activities and Recent VNS Therapy Publications
Devices Neurology

HSMN NewsFeed - 18 May 2006
Conor Medsystems Announces First Patient Treated with Dual-Drug Coronary Stent
Devices Interventional Cardiology

HSMN NewsFeed - 11 May 2006
Conor Medsystems Initiates RAPID Clinical Study for First Pimecrolimus Drug-Eluting Stent
Devices Interventional Cardiology

HSMN NewsFeed - 10 May 2006
Theregen's Heart Patch of Living Cells Successfully Placed on First Patient
Devices Regenerative Medicine Cardiology

HSMN NewsFeed - 9 May 2006
Gendux AB and Introgen Therapeutics File European Orphan Drug Designation for ADVEXIN
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 May 2006
Introgen's ADVEXIN p53 Therapy Provided to Cancer Patients With Li-Fraumeni Syndrome
Biopharmaceuticals Oncology FDA

Return to NewsFeed

Additional items found! 195

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 195 additional stories matching:
cytokines
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.